PR88137

SHANGHAI, Feb. 19, 2021 /PRNewswire=KYODO JBN/ --

Regor Therapeutics, a clinical stage biotechnology company dedicated to the

discovery of innovative medicines to treat cancer, immune disorders and

metabolic diseases, announces the successful completion of $90 million Series B

financing.

Founded in July of 2018 by a group of veteran drug hunters with extensive

research and executive leadership experiences at top multinational

pharmaceutical companies, Regor aims to establish world-class innovation

capabilities and is committed to delivering clinically differentiated, best-

and first-in-class drugs to serve patients globally.  By leveraging CARD,

Computer Accelerated Rational Discovery, a proprietary enabling technology

platform, the team has successfully advanced numerous discovery programs in a

dramatically accelerated fashion, including from ideas to a clinical start in

two years.

The Series B financing was led by Lilly Asia Ventures and included

participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex

Ventures China. Regor Therapeutics was established with initial series A

strategic investment from Qilu Pharmaceutical Group, a well-known Chinese

pharmaceutical company.

"We are very pleased with the strong support from leading life science

investment firms in this financing round. We are now in a strong position to

advance pre-clinical and clinical studies of multiple programs," said Dr.

Xiayang Qiu, Founder and CEO of Regor. "We are looking forward to long-term

collaborations with our investors, as we aim to improve the treatment outcomes

for worldwide patients of chronic diseases, cancer and other life-threatening

diseases."

"We are proud to support Regor Therapeutics' world-class team to expand its

efforts across a larger number of programs and therapeutic areas to develop

tomorrow's life-saving treatments," said Dr. Yi Shi, managing partner of Lilly

Asia Ventures.

"With the next decade comes a historical moment for China's leap upwards. We

are delighted to collaborate with veteran scientists, leading entrepreneurs and

investment partners in biopharma industry. Together we are working hard for a

better world by innovative and transformative medicines which make meaningful

impacts to patients globally," said Mr. Andy Lin, founding partner of Loyal

Valley Capital.

About Regor Therapeutics Group

Regor Therapeutics is a clinical stage company dedicated to the discovery and

development of innovative and clinically differentiated medicines by leveraging

the proprietary CARD (Computer Accelerated Rational Discovery) Platform,

seamlessly integrating structural biology, computational chemistry, therapeutic

biology, medicinal chemistry, and clinical development. Regor has assembled a

world-class scientific team and demonstrated high efficiency in producing best-

and first-in-class molecules.

About Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded

in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to

become the trusted partner for exceptional entrepreneurs seeking smart capital

and to build great companies developing breakthrough products that treat

diseases and improve human health.

About Loyal Valley Capital

Loyal Valley Capital ("LVC"), founded in 2015, is a thematic, research-oriented

private equity firm that has been a "partner of choice" for China's most

promising companies. LVC has left a mark in leading players such as Tik Tok,

Didi, Bilibili, Junshi, InnoCare, Akeso, Pop Mart, SUPCON. In 2020, LVC was

honorably awarded the "Top 10 Most Influential Private Equity Firms in China",

"Top 20 Healthcare Investor in China", "Top 10 Innovative Drug Investor in

China", and "Top 20 Consumer Investor in China".

About Lanting Capital

LanTing Capital (LTC) is a cross-border, pharmaceutical-focused strategic

private equity firm. Founded by pharmaceutical veterans and asset management

experts, LTC leverages our unparalleled industry knowledge and network plus

deep financial market know-how across the USA, China and Europe to unlock

unique cross-border growth opportunities for our portfolio companies and

investors. LanTing is currently operating in Princeton (USA), Milan (Italy),

Saanen (Switzerland), and Hangzhou (China).

About TF Capital

TF Capital focuses on investment in the life sciences industry, primarily

investing in early-stage companies with high potential.  Through strategic

investments in various key areas and right partnerships, TF Capital hopes to

capture opportunities in the rapidly expanding Chinese life sciences market.

Our investment team has vast experience and resources in industry to assist our

portfolio companies.

About Vertex Ventures China

Vertex Ventures is a global network of venture capital funds, who is a member

of Tamasek Holdings. The operator-investors manage portfolios in China, the

U.S., Israel, India and Southeast Asia. Vertex Ventures China, founded in 2008,

has offices in Beijing, Shanghai and Shenzhen. It is currently managing both

Dollar and RMB funds, with assets under management of over ¥10 billion. Vertex

Ventures China invests in high-growth innovative start-ups across mainland

China, covering the fields of deep tech, new digital economy and healthcare.

Some of its notable investments include 91 Wireless, Chipscreen, mobike,

Horizon Robotics, Harbour Biomed, Changba, Edge Medical, Inmagene, Infinovo,

etc.

www.regor.com

Source: Regor Therapeutics Group